A retrospective analysis to estimate target trough concentration of vancomycin for febrile neutropenia in patients with hematological malignancy

作者：Suzuki Yosuke^*; Tokimatsu Issei; Morinaga Yuko; Sato Yuhki; Takano Kuniko; Kohno Kazuhiro; Ogata Masao; Hiramatsu Kazufumi; Itoh Hiroki; Kadota Jun ichi

来源：Clinica Chimica Acta, 2015, 440: 183-187.

DOI：10.1016/j.cca.2014.11.027

• Vancomycin
• Therapeutic drug monitoring
• Febrile neutropenia
• Hematological malignancy

Background: The target trough concentration of vancomycin in patients with febrile neutropenia has not been reported. The aim of this study was to estimate the target trough concentration for febrile neutropenia in patients with hematological malignancy.
Methods: In this retrospective, single-center, observational cohort study, 63 hospitalized patients with hematological malignancy who were treated with vancomycin for febrile neutropenia due to bacteriologically documented or presumptive Gram-positive infections were analyzed.
Results: A significant difference in the first trough concentration of vancomycin was observed between the response and non-response groups, and between the nephrotoxicity and non-nephrotoxicity groups. Multiple logistic regression analyses identified the first trough concentration as the only independent variable associated with clinical efficacy and nephrotoxicity of vancomycin. The areas under the ROC curves were 0.72 and 0.83 for clinical efficacy and nephrotoxicity, respectively. The cut-off values of the first trough concentration were 11.1 mu g/ml for clinical efficacy (sensitivity 60%, specificity 87%) and 11.9 mu g/ml for nephrotoxicity (sensitivity 77%, specificity 82%).
Conclusions: These results suggest a relationship of trough vancomycin concentration with clinical efficacy and incidence of nephrotoxicity. We propose a target trough vancomycin concentration of around 11.5 mu g/ml for febrile neutropenia in patients with hematological malignancy.

• 出版日期2015-2-2